Management of Immunocompromised Patients with Influenza

Introduction to Influenza Treatment

The National Comprehensive Cancer Network recommends initiating oseltamivir immediately for all immunocompromised patients with suspected or confirmed influenza, regardless of symptom duration 1, 2.
Immunocompromised patients benefit from antiviral therapy even when started beyond 48 hours after symptom onset, with significant mortality reduction (OR 0.21) 1, 3.
Treatment should be started empirically without waiting for laboratory confirmation during influenza season 2, 3.

The National Comprehensive Cancer Network recommends standard oseltamivir dosing is 75 mg twice daily for 5 days in adults 2, 3.
Longer courses (e.g., 10 days) and treatment until resolution of symptoms should be considered in immunocompromised patients, though this remains controversial 2.
Some centers use higher doses (150 mg twice daily) in immunocompromised patients with mixed results 2.

The National Comprehensive Cancer Network reports a 50% reduction in pneumonia risk 2, 3.
Significant mortality benefit in high-risk patients 3.
Reduced viral shedding and transmission risk 3.
The American College of Physicians recommends against withholding antiviral therapy while waiting for laboratory confirmation in immunocompromised patients 2, 3.
The American College of Physicians recommends against automatically discontinuing CellCept without considering graft rejection risk—this decision requires careful individualized assessment 1.
The Centers for Disease Control and Prevention recommend against using corticosteroids as adjunctive therapy for influenza treatment unless clinically indicated for other reasons, as they are not beneficial and may prolong viral shedding 1.
The Centers for Disease Control and Prevention recommend against delaying antiviral therapy beyond 48 hours when possible, though benefit persists even with later initiation 1, 3.